UnitedHealth Group Incorporated (UNH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 9/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.46% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- UnitedHealth Group (UNH) Expands Medicare Advantage, Is It A Bargain?
- UnitedHealth Reports on Oct. 13. Here's the 1 Number I'm Watching.
- UnitedHealth Group (UNH) Surpasses Market Returns: Some Facts Worth Knowing
- UnitedHealth and Humana cutting Medicare Advantage plans in 2027
- UnitedHealth Trades at $365 as It Shuts Plans for 390,000 Medicare Advantage Members. Here’s What It Signals for 2027
- UnitedHealth Group (UNH) Dips More Than Broader Market: What You Should Know
- Sector Update: Healthcare Stocks Fall Late Afternoon
- Judge Denies In Part UnitedHealth's Motion to Dismiss CalPERS Suit
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for UnitedHealth Group Incorporated.
Full UNH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.